Psychedelic Research & Clinical Trials

Sunstone is establishing the gold standard for psychedelic clinics to ensure that the delivery of psychedelic-assisted therapy is patient-centric, responsible, safe, and effective.
View All Trials
Sunstone designs and delivers innovative clinical trials with leading psychedelic drug developers and medical bodies.
  • Beckley Psytech
  • COMPASS Pathways
  • Cybin
  • Lykos Therapeutics
  • MindMed
  • Reunion Neuroscience
  • Transcend Therapeutics
  • Usona Institute
We work with a broad range of psychedelics.
  • Psilocybin
  • MDMA
  • LSD
  • 5-MeO-DMT
  • Methylone
Across a wide array of clinical indications.
  • Adjustment Disorder (AD)
  • Demoralization in Patients with Cancer
  • Palliative Care (End of Life)
  • Generalized Anxiety Disorder (GAD)
  • Major Depressive Disorder (MDD)
  • Major Depressive Disorder in Patients with Cancer
  • Post-Traumatic Stress Disorder (PTSD)
  • Postpartum Depression
  • Treatment-Resistant Depression (TRD)
In partnership with top-tier academic and medical institutions.
  • Adventist HealthCare
  • Dana-Farber Cancer Institute
  • Johns Hopkins Center for Psychedelic & Consciousness Research
  • McGill University
  • Memorial Sloan Kettering Cancer Center
  • The University of Vermont

Sunstone is Developing and Refining the Standards of Patient Care

Discover the Patient Experience

Industry Leadership: A Wide Breadth of Clinical Trials

Treatment Indications
PTSD (Post-Traumatic Stress Disorder)
Palliative Care (End of Life)
MDD (Major Depressive Disorder)
TRD (Treatment-Resistant Depression)
AD (Adjustment Disorder)
GAD (Generalized Anxiety Disorder)
Postpartum Depression
Active Trials in 2024

The Sunstone Difference

At our core, Sunstone is a company dedicated to learning and innovation. Everything we do is reflective, deliberate, and intentional.


We are building a scalable platform with state-of-the-art centers that champion clinical trials and showcase the clinic of the future—which we believe is the best way to ensure long-term acceptance of these new therapies


Sunstone is a leader in the delivery of psychedelic-assisted therapy in the medical setting, offering a business model that can make care more widely available. We are focusing on the development and execution of clinical trials today and moving toward clinical delivery if and when therapies are approved.

Research-Informed Care

Sunstone designs and delivers clinical trials across multiple medicines and treatment indications to inform patient experience and FDA regulation. We are setting the bar high with an absolute commitment to providing a safe, trustworthy space for psychedelic-assisted therapy


Sunstone has the most open clinical trials and has treated more patients with psychedelics (excluding ketamine) than any other clinic or center in the country. Learnings from our clinical trials help us develop new standards for delivery in this emerging field and deliver immersive training simulations and education, focusing on all aspects of delivery.

Operational Rigor

The administration of psychedelic therapies is complex, necessitating extensive expertise in logistics, infrastructure, training, and clinical intervention. Sunstone’s experience in oncology care affords us a distinct and effective approach to these challenges. We maintain a detailed and efficient approach to planning, delivering, and measuring outcomes.